In a deal that goes beyond the traditional industry-academia partnership, Vanderbilt University, in Nashville, and Janssen Pharmaceutica, the mental health arm of Johnson & Johnson, have partnered to develop schizophrenia treatments.
The research lab of Jeffrey Conn, director of Vanderbilt's Program in Drug Discovery, will receive $10 million from an up-front payment and other funding from Janssen. The lab stands to receive further milestone payments during the three-year pact. Janssen gains an exclusive license to existing compounds that act on a neurotransmitter target and could license and develop future molecules discovered in the collaboration.
Read More: Unique Deal Reflects Novel Drug Discovery Program at Vanderbilt University